Robert D. Morgan

2.6k total citations
67 papers, 1.6k citations indexed

About

Robert D. Morgan is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, Robert D. Morgan has authored 67 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 23 papers in Reproductive Medicine and 21 papers in Surgery. Recurrent topics in Robert D. Morgan's work include Ovarian cancer diagnosis and treatment (23 papers), PARP inhibition in cancer therapy (16 papers) and BRCA gene mutations in cancer (12 papers). Robert D. Morgan is often cited by papers focused on Ovarian cancer diagnosis and treatment (23 papers), PARP inhibition in cancer therapy (16 papers) and BRCA gene mutations in cancer (12 papers). Robert D. Morgan collaborates with scholars based in United Kingdom, United States and Italy. Robert D. Morgan's co-authors include John M. O’Callaghan, Simon Knight, Peter J. Morris, Ian Zachary, Srijita Sen‐Chowdhry, John C. Chambers, William J. McKenna, Andrew R. Clamp, Gordon C. Jayson and Stephen S. Taylor and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Cell and Annals of Surgery.

In The Last Decade

Robert D. Morgan

62 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert D. Morgan United Kingdom 23 506 391 382 224 223 67 1.6k
Luis Isola United States 33 907 1.8× 693 1.8× 360 0.9× 701 3.1× 80 0.4× 99 4.0k
Cheng‐Keng Chuang Taiwan 30 516 1.0× 674 1.7× 876 2.3× 104 0.5× 113 0.5× 202 3.0k
Julie Blatt United States 32 797 1.6× 757 1.9× 686 1.8× 686 3.1× 88 0.4× 142 3.5k
Thomas Schreiner Norway 31 141 0.3× 446 1.1× 314 0.8× 315 1.4× 90 0.4× 84 2.8k
Paul V. Woolley United States 24 764 1.5× 606 1.5× 261 0.7× 62 0.3× 153 0.7× 80 2.2k
Michael Becker Germany 21 305 0.6× 941 2.4× 404 1.1× 86 0.4× 41 0.2× 63 2.6k
Suzanne Hughes Australia 28 403 0.8× 826 2.1× 248 0.6× 148 0.7× 178 0.8× 45 2.5k
Matthew Burnell United Kingdom 25 1.1k 2.2× 637 1.6× 453 1.2× 327 1.5× 87 0.4× 66 3.3k
Sandeep Mahajan India 27 477 0.9× 702 1.8× 132 0.3× 137 0.6× 73 0.3× 118 2.4k
Michael Schwartz United States 28 1.9k 3.7× 617 1.6× 794 2.1× 111 0.5× 145 0.7× 83 4.2k

Countries citing papers authored by Robert D. Morgan

Since Specialization
Citations

This map shows the geographic impact of Robert D. Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert D. Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert D. Morgan more than expected).

Fields of papers citing papers by Robert D. Morgan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert D. Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert D. Morgan. The network helps show where Robert D. Morgan may publish in the future.

Co-authorship network of co-authors of Robert D. Morgan

This figure shows the co-authorship network connecting the top 25 collaborators of Robert D. Morgan. A scholar is included among the top collaborators of Robert D. Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert D. Morgan. Robert D. Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morgan, Robert D., Xin Wang, Jurjees Hasan, et al.. (2024). Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer. British Journal of Cancer. 131(12). 1919–1927. 5 indexed citations
2.
Morgan, Robert D., George J. Burghel, Hélene Schlecht, et al.. (2024). Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene. Genetics in Medicine. 26(10). 101230–101230. 5 indexed citations
3.
Crosbie, Emma J., Emma R. Woodward, Fiona Lalloo, et al.. (2023). MSH2 is the very young onset ovarian cancer predisposition gene, not BRCA1. Journal of Medical Genetics. 60(6). 576–577. 2 indexed citations
4.
Nelson, Louisa, Anthony Tighe, Samantha Littler, et al.. (2023). Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability. Chromosome Research. 31(3). 21–21. 5 indexed citations
5.
Adamson, A. W., Yuan Chun Ding, Linda Steele, et al.. (2023). Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer. Journal of Ovarian Research. 16(1). 141–141. 6 indexed citations
6.
Morgan, Robert D., George J. Burghel, Michael Bulman, et al.. (2023). Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?. Cancers. 15(3). 730–730. 2 indexed citations
7.
Nelson, Louisa, et al.. (2022). Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors. NAR Cancer. 4(4). zcac036–zcac036. 7 indexed citations
8.
Morgan, Robert D., Cristina Ferreras, Isabel Peset, et al.. (2022). c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. BMC Medicine. 20(1). 59–59. 5 indexed citations
9.
Ye, Weiyu, Anna Olsson‐Brown, Robert Watson, et al.. (2021). Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. British Journal of Cancer. 124(10). 1661–1669. 33 indexed citations
10.
Morgan, Robert D., Louisa Nelson, Anthony Tighe, et al.. (2021). Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models. Journal of Experimental & Clinical Cancer Research. 40(1). 323–323. 26 indexed citations
11.
Morgan, Robert D., et al.. (2021). DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy. Progress in Biophysics and Molecular Biology. 163. 160–170. 20 indexed citations
12.
Morgan, Robert D., et al.. (2021). The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. British Journal of Cancer. 126(6). 851–864. 10 indexed citations
13.
Morgan, Robert D., Susana Banerjee, Marcia Hall, et al.. (2020). Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecologic Oncology. 156(3). 545–551. 18 indexed citations
14.
Morgan, Robert D., Richard Welch, Claire Mitchell, et al.. (2019). Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer. ESMO Open. 4(2). e000463–e000463. 7 indexed citations
15.
O’Callaghan, John M., Simon Knight, Robert D. Morgan, & Peter J. Morris. (2016). A National Registry Analysis of Kidney Allografts Preserved With Marshall’s Solution in the United Kingdom. Transplantation. 100(11). 2447–2452. 6 indexed citations
16.
Califano, Raffaele, Keith M. Kerr, Robert D. Morgan, et al.. (2016). Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Current Oncology Reports. 18(9). 59–59. 29 indexed citations
17.
O’Callaghan, John M., et al.. (2012). Preservation Solutions for Static Cold Storage of Kidney Allografts: A Systematic Review and Meta-Analysis. American Journal of Transplantation. 12(4). 896–906. 80 indexed citations
18.
Harrison, Neil A., Robert D. Morgan, & Hugo Critchley. (2010). From facial mimicry to emotional empathy: A role for norepinephrine ?. Social Neuroscience. 5(4). 393–400. 29 indexed citations
19.
Morgan, Robert D., et al.. (2000). Abnormal Uptake of I-131 Mimicking Salivary Gland Uptake in a Patient With Diffuse Dental Disease. Clinical Nuclear Medicine. 25(4). 314–315. 3 indexed citations
20.
Prevel, Christopher D., et al.. (1996). Biomechanical Testing of Titanium Self-Tapping Versus Pretapped Lag Screw Fixation of Spiral Metacarpal Fractures. Annals of Plastic Surgery. 37(1). 34–40. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luis Isola Breakdown of academic impact, for papers by Cheng‐Keng Chuang Breakdown of academic impact, for papers by Julie Blatt Breakdown of academic impact, for papers by Thomas Schreiner Breakdown of academic impact, for papers by Paul V. Woolley Breakdown of academic impact, for papers by Michael Becker Breakdown of academic impact, for papers by Suzanne Hughes Breakdown of academic impact, for papers by Matthew Burnell Breakdown of academic impact, for papers by Sandeep Mahajan Breakdown of academic impact, for papers by Michael Schwartz
Rankless by CCL
2026